Arch Biopartners Inc
XTSX:ARCH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (32.9), the stock would be worth CA$0.08 (83% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 192.6 | CA$0.46 |
0%
|
| 3-Year Average | 32.9 | CA$0.08 |
-83%
|
| 5-Year Average | 47.3 | CA$0.11 |
-75%
|
| Industry Average | 8.5 | CA$0.02 |
-96%
|
| Country Average | 2.9 | CA$0.01 |
-98%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
CA$38.8m
|
/ |
Jan 2026
CA$158.1k
|
= |
|
|
CA$38.8m
|
/ |
Sep 2028
CA$85.7m
|
= |
|
|
CA$38.8m
|
/ |
Sep 2029
CA$181.7m
|
= |
|
|
CA$38.8m
|
/ |
Sep 2030
CA$290.2m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Arch Biopartners Inc
XTSX:ARCH
|
30.5m CAD | 192.6 | -11.3 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
958.5B USD | 335.6 | 3 973.8 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.7B USD | 3.9 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.7B USD | 5.1 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 18.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
299.9B CNY | 6.6 | 15.7 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
33.5B CHF | 5.1 | -120.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.5B USD | 4.6 | 25.2 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.5B USD | 9.3 | 45.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27B USD | 1.7 | 19.9 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.7B USD | 6.4 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.4 |
| Median | 2.9 |
| 70th Percentile | 4.9 |
| Max | 15 623 917.6 |
Other Multiples
Arch Biopartners Inc
Glance View
Arch Biopartners, Inc. operates as a biotechnology company. The company is headquartered in Toronto, Ontario. The firm is focused on the development of technologies that make a medical or commercial impact. Its lead drug candidate Metablok is formed to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys, which often results in organ damage or failure, including in the case of sepsis and corona virus disease-2019 (COVID-19). Its drug candidate also includes AB569, Borg and MetaMx. Its AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and wounds. The Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Its MetaMx is a synthetic molecules that target brain tumor initiating cells and invasive glioma cells.
